Zealand Pharma announces the ending of enrollment in the 2B Zupreme-1 Phase-1 test of petelintide in people with overweight or obesity

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.